Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?

Introduction: Familial Mediterranean fever (FMF) patients had 5–10% colchicine resistance. Although FMF attacks are characterized by acute phase elevation, there are no biomarkers that can show colchicine resistance yet. The serum endocan levels may elevate in inflammatory and auto-inflammatory dise...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ahmet Omma, Berkan Armaǧan, Serdar Can Güven, Sevinç Can Sandıkçı, Seda Çolak, Çiǧdem Yücel, Orhan Küçükşahin, Abdulsamet Erden
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	endocan FMF attacks novel biomarker colchicine responsiveness colchicine resistance FMF Pediatrics RJ1-570
Acceso en línea:	https://doaj.org/article/21502cd033e344058d6aff87599b5b24
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:21502cd033e344058d6aff87599b5b24
record_format	dspace
spelling	oai:doaj.org-article:21502cd033e344058d6aff87599b5b242021-12-01T13:53:02ZEndocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?2296-236010.3389/fped.2021.788864https://doaj.org/article/21502cd033e344058d6aff87599b5b242021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fped.2021.788864/fullhttps://doaj.org/toc/2296-2360Introduction: Familial Mediterranean fever (FMF) patients had 5–10% colchicine resistance. Although FMF attacks are characterized by acute phase elevation, there are no biomarkers that can show colchicine resistance yet. The serum endocan levels may elevate in inflammatory and auto-inflammatory diseases.Objectives: This study aimed to evaluate serum endocan levels in FMF patients according to whether attack and colchicine resistance or not and also compare them with classical acute phase reactants.Methods: In this single-center and cross-sectional study, a total of 111 FMF patients and 60 healthy individuals were enrolled. All patients' basic demographic and clinical data were recorded and blood samples were collected.Results: A total of 46 (41.4%) FMF patients had colchicine resistance. In comparison to the FMF patients according to colchicine response, colchicine resistance patients had a significantly higher median (IQR) endocan levels than colchicine responsive patients [36.98 ng/ml (97.41) vs. 13.57 ng/ml (27.87), p = 0.007], but there were no differences between in terms of median ESR and CRP levels. Inversely, serum endocan levels were similar during an attack and attack-free period in FMF patients, although ESR and CRP levels were significantly different. Interestingly, the highest serum endocan levels were in the control group.Conclusion: In conclusion, serum endocan levels were higher in colchicine resistance than colchicine responsive patients, but attack state had no effect on serum endocan levels in our study. Unlike ESR and CRP, serum endocan may be a novel biomarker for detection of colchicine resistance and distinguish the FMF attacks.Ahmet OmmaBerkan ArmaǧanSerdar Can GüvenSevinç Can SandıkçıSeda ÇolakÇiǧdem YücelOrhan KüçükşahinAbdulsamet ErdenFrontiers Media S.A.articleendocanFMF attacksnovel biomarkercolchicine responsivenesscolchicine resistanceFMFPediatricsRJ1-570ENFrontiers in Pediatrics, Vol 9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	endocan FMF attacks novel biomarker colchicine responsiveness colchicine resistance FMF Pediatrics RJ1-570
spellingShingle	endocan FMF attacks novel biomarker colchicine responsiveness colchicine resistance FMF Pediatrics RJ1-570 Ahmet Omma Berkan Armaǧan Serdar Can Güven Sevinç Can Sandıkçı Seda Çolak Çiǧdem Yücel Orhan Küçükşahin Abdulsamet Erden Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?
description	Introduction: Familial Mediterranean fever (FMF) patients had 5–10% colchicine resistance. Although FMF attacks are characterized by acute phase elevation, there are no biomarkers that can show colchicine resistance yet. The serum endocan levels may elevate in inflammatory and auto-inflammatory diseases.Objectives: This study aimed to evaluate serum endocan levels in FMF patients according to whether attack and colchicine resistance or not and also compare them with classical acute phase reactants.Methods: In this single-center and cross-sectional study, a total of 111 FMF patients and 60 healthy individuals were enrolled. All patients' basic demographic and clinical data were recorded and blood samples were collected.Results: A total of 46 (41.4%) FMF patients had colchicine resistance. In comparison to the FMF patients according to colchicine response, colchicine resistance patients had a significantly higher median (IQR) endocan levels than colchicine responsive patients [36.98 ng/ml (97.41) vs. 13.57 ng/ml (27.87), p = 0.007], but there were no differences between in terms of median ESR and CRP levels. Inversely, serum endocan levels were similar during an attack and attack-free period in FMF patients, although ESR and CRP levels were significantly different. Interestingly, the highest serum endocan levels were in the control group.Conclusion: In conclusion, serum endocan levels were higher in colchicine resistance than colchicine responsive patients, but attack state had no effect on serum endocan levels in our study. Unlike ESR and CRP, serum endocan may be a novel biomarker for detection of colchicine resistance and distinguish the FMF attacks.
format	article
author	Ahmet Omma Berkan Armaǧan Serdar Can Güven Sevinç Can Sandıkçı Seda Çolak Çiǧdem Yücel Orhan Küçükşahin Abdulsamet Erden
author_facet	Ahmet Omma Berkan Armaǧan Serdar Can Güven Sevinç Can Sandıkçı Seda Çolak Çiǧdem Yücel Orhan Küçükşahin Abdulsamet Erden
author_sort	Ahmet Omma
title	Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?
title_short	Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?
title_full	Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?
title_fullStr	Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?
title_full_unstemmed	Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?
title_sort	endocan: a novel marker for colchicine resistance in familial mediterranean fever patients?
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/21502cd033e344058d6aff87599b5b24
work_keys_str_mv	AT ahmetomma endocananovelmarkerforcolchicineresistanceinfamilialmediterraneanfeverpatients AT berkanarmagan endocananovelmarkerforcolchicineresistanceinfamilialmediterraneanfeverpatients AT serdarcanguven endocananovelmarkerforcolchicineresistanceinfamilialmediterraneanfeverpatients AT sevinccansandıkcı endocananovelmarkerforcolchicineresistanceinfamilialmediterraneanfeverpatients AT sedacolak endocananovelmarkerforcolchicineresistanceinfamilialmediterraneanfeverpatients AT cigdemyucel endocananovelmarkerforcolchicineresistanceinfamilialmediterraneanfeverpatients AT orhankucuksahin endocananovelmarkerforcolchicineresistanceinfamilialmediterraneanfeverpatients AT abdulsameterden endocananovelmarkerforcolchicineresistanceinfamilialmediterraneanfeverpatients
_version_	1718405044414447616

Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?

Ejemplares similares